首页> 美国卫生研究院文献>Micromachines >A 3D Printed Self-Sustainable Cell-Encapsulation Drug Delivery Device for Periocular Transplant-Based Treatment of Retinal Degenerative Diseases
【2h】

A 3D Printed Self-Sustainable Cell-Encapsulation Drug Delivery Device for Periocular Transplant-Based Treatment of Retinal Degenerative Diseases

机译:用于眼周移植物治疗视网膜退行性疾病的3D打印的自持性细胞封装药物输送装置

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Self-sustainable release of brain-derived neurotrophic factor (BDNF) to the retina using minimally invasive cell-encapsulation devices is a promising approach to treat retinal degenerative diseases (RDD). Herein, we describe such a self-sustainable drug delivery device with human retinal pigment epithelial (ARPE-19) cells (cultured on collagen coated polystyrene (PS) sheets) enclosed inside a 3D printed semi-porous capsule. The capsule was 3D printed with two photo curable polymers: triethylene glycol dimethacrylate (TEGDM) and polyethylene glycol dimethylacrylate (PEGDM). The capsule’s semi-porous membrane (PEGDM) could serve three functions: protecting the cells from body’s immune system by limiting diffusion (5.97 ± 0.11%) of large molecules like immunoglobin G (IgG)(150 kDa); helping the cells to survive inside the capsule by allowing diffusion (43.20 ± 2.16%) of small molecules (40 kDa) like oxygen and necessary nutrients; and helping in the treatment of RDD by allowing diffusion of cell-secreted BDNF to the outside environment. In vitro results showed a continuous BDNF secretion from the device for at least 16 days, demonstrating future potential of the cell-encapsulation device for the treatment of RDD in a minimally invasive and self-sustainable way through a periocular transplant.
机译:使用微创细胞封装设备将脑源性神经营养因子(BDNF)自我持续释放到视网膜是治疗视网膜退行性疾病(RDD)的一种有前途的方法。在本文中,我们描述了一种具有人类视网膜色素上皮(ARPE-19)细胞(培养在胶原蛋白涂层的聚苯乙烯(PS)板上)的自我可持续的药物递送装置,该细胞封装在3D打印的半多孔胶囊中。用两种可光固化的聚合物对胶囊进行3D打印:三乙二醇二甲基丙烯酸酯(TEGDM)和聚乙二醇二甲基丙烯酸酯(PEGDM)。胶囊的半多孔膜(PEGDM)可以发挥三项功能:限制免疫球蛋白G(IgG)(150 kDa)等大分子的扩散(5.97±0.11%),从而保护细胞免受人体免疫系统的侵害;通过允许小分子(40 kDa)(如氧气和必需的营养物质)扩散(43.20±2.16%)来帮助细胞在胶囊内存活;并通过使细胞分泌的BDNF扩散到外部环境来帮助治疗RDD。体外结果显示该装置连续分泌BDNF至少持续16天,这表明该细胞封装装置通过眼周移植以微创且可自我维持的方式治疗RDD的未来潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号